InterMune, Vidara Therapeutics deal

InterMune will divest to Vidara worldwide rights to develop and commercialize Actimmune interferon (IFN) gamma-1b for $55 million in cash. InterMune is also eligible for tiered royalties for two years, which the company said could add about 5% to the purchase price. InterMune said the deal will provide additional capital for the registration and commercialization of its idiopathic pulmonary fibrosis (IPF) drug Esbriet pirfenidone, as well as for its R&D programs. The deal is expected to close this quarter. Locust Walk Partners is advising InterMune. ...